

Larry W Kwak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3297975/publications.pdf>

Version: 2024-02-01

204
papers

13,527
citations

25423

59
h-index

26792

111
g-index

207
all docs

207
docs citations

207
times ranked

15936
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 89-97. | 0.2 | 6 |
| 2 | A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 1289-1301. | 0.6 | 9 |
| 3 | CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1015-1024. | 3.3 | 15 |
| 4 | Immortalized B Cells Transfected With mRNA of Antigen Fused to MITD (IBMAM): An Effective Immunological Tool for In-Vitro Immune-Monitoring of Antigen-specific T Cells. <i>JCO Global Oncology</i> , 2022, 8, 21-21. | 0.8 | 0 |
| 5 | The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. <i>Cancer Immunology Research</i> , 2021, 9, 75-88. | 1.6 | 24 |
| 6 | Double-hit Signature with <i>TP53</i> Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP. <i>Clinical Cancer Research</i> , 2021, 27, 1671-1680. | 3.2 | 24 |
| 7 | Targeted In Vivo Delivery of NF- κ B Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy. <i>Molecular Therapy</i> , 2021, 29, 1214-1225. | 3.7 | 6 |
| 8 | Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study. <i>Blood Advances</i> , 2021, 5, 3354-3361. | 2.5 | 6 |
| 9 | Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2139-2145. | 2.0 | 14 |
| 10 | Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 1034-1044. | 3.2 | 48 |
| 11 | The changing investment in translational science by academic medical centers: HOPE in the Valley of Death. <i>Journal of Clinical Investigation</i> , 2020, 130, 3333-3335. | 3.9 | 5 |
| 12 | Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma. <i>Blood</i> , 2020, 136, 27-28. | 0.6 | 1 |
| 13 | A Novel Therapeutic DNA Vaccine Elicits Reduction of Tumor Clones and Favorable Perturbations in the Immune Microenvironment in Patients (pts) with Untreated Smoldering Waldenström Macroglobulinemia (sWM). <i>Blood</i> , 2020, 136, 6-7. | 0.6 | 0 |
| 14 | CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019, 11, . | 5.8 | 67 |
| 15 | Long-term overall and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 670-678. | 1.2 | 7 |
| 16 | Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. <i>Blood</i> , 2019, 133, 306-318. | 0.6 | 26 |
| 17 | B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. <i>Molecular Therapy</i> , 2018, 26, 695-707. | 3.7 | 25 |
| 18 | Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. <i>Cancer</i> , 2018, 124, 2561-2569. | 2.0 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies <i>in Vivo</i> . <i>Clinical Cancer Research</i> , 2018, 24, 1114-1123. | 3.2 | 25 |
| 20 | Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 514-520. | 2.0 | 31 |
| 21 | Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology</i> , 2018, 5, e543-e553. | 2.2 | 53 |
| 22 | Targeting myeloid-derived suppressor cells for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1181-1195. | 2.0 | 95 |
| 23 | Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2018, 11, 87. | 6.9 | 12 |
| 24 | Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. <i>BMC Cancer</i> , 2018, 18, 187. | 1.1 | 16 |
| 25 | Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1636-1636. | 0.6 | 5 |
| 26 | Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. <i>Blood</i> , 2018, 132, 1411-1411. | 0.6 | 0 |
| 27 | Absence of Grail promotes CD8+ T cell anti-tumour activity. <i>Nature Communications</i> , 2017, 8, 239. | 5.8 | 22 |
| 28 | CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. <i>Cancer Research</i> , 2017, 77, 5118-5128. | 0.4 | 34 |
| 29 | Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1861-1869. | 2.0 | 19 |
| 30 | Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e362-e373. | 2.2 | 70 |
| 31 | Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. <i>Cell Research</i> , 2017, 27, 1034-1045. | 5.7 | 259 |
| 32 | Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-31. | 0.8 | 152 |
| 33 | Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017, 130, 738-738. | 0.6 | 5 |
| 34 | Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 7532-7532. | 0.8 | 2 |
| 35 | Overview of lymphoma. , 2017, , 1-9. | | 0 |
| 36 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90. | | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. <i>Immunity</i> , 2016, 44, 913-923. | 6.6 | 120 |
| 38 | IL-15 enhances the antitumor effect of human antigen-specific CD8+ T cells by cellular senescence delay. <i>Oncolmmunology</i> , 2016, 5, e1237327. | 2.1 | 17 |
| 39 | Rituximab plus hyperâ€œ<sc>CVAD</sc> alternating with <sc>MTX</sc>/Araâ€œ in patients with newly diagnosed mantle cell lymphoma: 15â€œyear followâ€œup of a phase <sc>II</sc> study from the <sc>MD</sc> Anderson Cancer Center. <i>British Journal of Haematology</i> , 2016, 172, 80-88. | 1.2 | 82 |
| 40 | Targeting B-cell malignancies through human B-cell receptor specific CD4+T cells. <i>Oncolmmunology</i> , 2016, 5, e1232220. | 2.1 | 5 |
| 41 | Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 445-447. | 0.6 | 5 |
| 42 | Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , 2016, 128, 1807-1807. | 0.6 | 11 |
| 43 | Quantitative Baseline Circulating Tumor DNA Levels Correlate with GM-CSF Response to Idiotypic Vaccine in Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 2943-2943. | 0.6 | 0 |
| 44 | Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, e272-e274. | 1.7 | 17 |
| 45 | CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 726-735. | 1.2 | 50 |
| 46 | Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 463-470. | 1.2 | 81 |
| 47 | Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, lowâ€œgrade Bâ€œcell lymphomas. <i>British Journal of Haematology</i> , 2015, 169, 814-823. | 1.2 | 5 |
| 48 | Phase <sc>II</sc> study of <sc>HCVIDD</sc>/<sc>MA</sc> in patients with newly diagnosed peripheral Tâ€œcell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 509-516. | 1.2 | 15 |
| 49 | Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a nextâ€œgeneration sequencing approach. <i>British Journal of Haematology</i> , 2015, 169, 689-693. | 1.2 | 36 |
| 50 | Targeting tumor-associated myeloid cells for cancer immunotherapy. <i>Oncolmmunology</i> , 2015, 4, e983961. | 2.1 | 9 |
| 51 | Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 152-158. | 0.2 | 34 |
| 52 | Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. <i>Blood</i> , 2015, 126, 519-519. | 0.6 | 9 |
| 53 | Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 522-522. | 0.6 | 3 |
| 54 | Anti-Î²2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy. <i>Oncotarget</i> , 2015, 6, 8567-8578. | 0.8 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. <i>Oncotarget</i> , 2015, 6, 34329-34341. | 0.8 | 123 |
| 56 | Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1961-1961. | 0.6 | 0 |
| 57 | Induction of p53-mediated transcription and apoptosis by exportin1 (XPO1) inhibition in mantle cell lymphoma. <i>Cancer Science</i> , 2014, 105, 795-801. | 1.7 | 81 |
| 58 | ⁹⁰ Yttrium-90-rituximab radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease. <i>British Journal of Haematology</i> , 2014, 167, 207-213. | 1.2 | 27 |
| 59 | Rush Hour Traffic: Directing T Cells to Tumor. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju301-dju301. | 3.0 | 0 |
| 60 | Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 69-77. | 5.1 | 518 |
| 61 | The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 112-116. | 1.2 | 50 |
| 62 | Osteoblastic niche supports the growth of quiescent multiple myeloma cells. <i>Blood</i> , 2014, 123, 2204-2208. | 0.6 | 66 |
| 63 | Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. <i>Nature Medicine</i> , 2014, 20, 676-681. | 15.2 | 199 |
| 64 | Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1311-1318. | 5.1 | 239 |
| 65 | Double hit lymphoma: the MD Anderson Cancer Center clinical experience. <i>British Journal of Haematology</i> , 2014, 166, 891-901. | 1.2 | 310 |
| 66 | Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. <i>International Journal of Cancer</i> , 2014, 135, 2834-2846. | 2.3 | 31 |
| 67 | The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma. <i>Biomaterials</i> , 2014, 35, 5491-5504. | 5.7 | 108 |
| 68 | Cloning Variable Region Genes of Clonal Lymphoma Immunoglobulin for Generating Patient-Specific Idiotype DNA Vaccine. <i>Methods in Molecular Biology</i> , 2014, 1139, 289-303. | 0.4 | 3 |
| 69 | Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes. <i>American Journal of Blood Research</i> , 2014, 4, 46-52. | 0.6 | 4 |
| 70 | Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 99-105. | 0.2 | 25 |
| 71 | Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 611-620. | 1.2 | 23 |
| 72 | The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 15-18. | 0.2 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function. <i>Journal of Immunology</i> , 2013, 191, 3641-3650. | 0.4 | 86 |
| 74 | Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. <i>Haematologica</i> , 2013, 98, 1458-1466. | 1.7 | 58 |
| 75 | <i>In Vitro</i> and <i>In Vivo</i> Therapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2494-2504. | 1.9 | 22 |
| 76 | Phase I study of vorinostat in combination with standard <i>CHOP</i> in patients with newly diagnosed peripheral T-cell lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 138-141. | 1.2 | 37 |
| 77 | Nonstereotyped Lymphoma B Cell Receptors Recognize Vimentin as a Shared Autoantigen. <i>Journal of Immunology</i> , 2013, 190, 4887-4898. | 0.4 | 45 |
| 78 | Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6882-6890. | 3.2 | 103 |
| 79 | Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma. <i>PLoS ONE</i> , 2013, 8, e69126. | 1.1 | 30 |
| 80 | Bone Marrow Stromal Cells Derived MCP-1 Reverses the Inhibitory Effects of Multiple Myeloma Cells on Osteoclastogenesis by Upregulating the RANK Expression. <i>PLoS ONE</i> , 2013, 8, e82453. | 1.1 | 8 |
| 81 | Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. <i>Journal of Clinical Oncology</i> , 2012, 30, 4161-4167. | 0.8 | 137 |
| 82 | T cells and T cell tumors efficiently generate antigen-specific cytotoxic T cell immunity when modified with an NKT ligand. <i>Oncolmmunology</i> , 2012, 1, 141-151. | 2.1 | 2 |
| 83 | p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction. <i>Cancer Research</i> , 2012, 72, 6393-6402. | 0.4 | 66 |
| 84 | Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. <i>Blood</i> , 2012, 119, 2568-2578. | 0.6 | 21 |
| 85 | Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. <i>Blood</i> , 2012, 119, 161-169. | 0.6 | 103 |
| 86 | Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. <i>Blood</i> , 2012, 120, 3783-3792. | 0.6 | 100 |
| 87 | Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. <i>British Journal of Haematology</i> , 2012, 159, 243-246. | 1.2 | 8 |
| 88 | Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. <i>Lancet Oncology</i> , The, 2012, 13, 716-723. | 5.1 | 274 |
| 89 | Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2012, 53, 50-56. | 0.6 | 26 |
| 90 | Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2776-2782. | 0.8 | 162 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4123-4128. | 0.6 | 70 |
| 92 | TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. <i>Blood</i> , 2012, 120, 1613-1623. | 0.6 | 33 |
| 93 | MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response. <i>Haematologica</i> , 2012, 97, 586-594. | 1.7 | 110 |
| 94 | Temporal and geographic variations of Waldenstrom macroglobulinemia incidence. <i>Cancer</i> , 2012, 118, 3793-3800. | 2.0 | 104 |
| 95 | Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. <i>Journal of Molecular Medicine</i> , 2012, 90, 695-706. | 1.7 | 50 |
| 96 | Bortezomib-resistant nuclear factor κ B expression in stem-like cells in mantle cell lymphoma. <i>Experimental Hematology</i> , 2012, 40, 107-118.e2. | 0.2 | 17 |
| 97 | Lymphoma Vaccine Therapy: Next Steps After a Positive, Controlled Phase III Clinical Trial. <i>Seminars in Oncology</i> , 2012, 39, 253-262. | 0.8 | 9 |
| 98 | Translational development of vaccination strategies in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 295-304. | 0.7 | 7 |
| 99 | Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2011, 154, 284-286. | 1.2 | 23 |
| 100 | Targeting cell surface μ 2₂-microglobulin by pentameric IgM antibodies. <i>British Journal of Haematology</i> , 2011, 154, 111-121. | 1.2 | 11 |
| 101 | An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma. <i>Journal of Controlled Release</i> , 2011, 155, 184-192. | 4.8 | 72 |
| 102 | Cancer Vaccines: Moving toward Prevention?. <i>Cancer Prevention Research</i> , 2011, 4, 954-956. | 0.7 | 2 |
| 103 | Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 2787-2794. | 0.8 | 230 |
| 104 | Idiotype Vaccination As Consolidation Therapy: Time for Integration Into Standard of Care for Follicular Lymphoma?. <i>Journal of Clinical Oncology</i> , 2011, 29, 4845-4846. | 0.8 | 11 |
| 105 | Targeting Human B-cell Malignancies through Ig Light Chain-Specific Cytotoxic T Lymphocytes. <i>Clinical Cancer Research</i> , 2011, 17, 5945-5952. | 3.2 | 9 |
| 106 | Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. <i>Stem Cell Research</i> , 2010, 5, 212-225. | 0.3 | 26 |
| 107 | Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R ϵ MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 200-208. | 1.2 | 213 |
| 108 | Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 47-53. | 1.2 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Prime-Boost Vaccination Using Chemokine-Fused gp120 DNA and HIV Envelope Peptides Activates Both Immediate and Long-Term Memory Cellular Responses in Rhesus Macaques. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-7. | 3.0 | 6 |
| 110 | Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 193-210. | 0.7 | 12 |
| 111 | Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2445-2452. | 1.1 | 45 |
| 112 | Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines. <i>Vaccine</i> , 2010, 28, 7970-7978. | 1.7 | 5 |
| 113 | Human-Like Mouse Models for Testing the Efficacy and Safety of Anti-Î²2-Microglobulin Monoclonal Antibodies to Treat Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 951-959. | 3.2 | 19 |
| 114 | Myeloma cell lineâ€‘derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma. <i>Blood</i> , 2009, 114, 3880-3889. | 0.6 | 31 |
| 115 | IGF-1R tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. <i>Blood</i> , 2009, 114, 360-370. | 0.6 | 50 |
| 116 | Cancer vaccines: up, down, â€‘ up again?. <i>Blood</i> , 2009, 113, 1-2. | 0.6 | 107 |
| 117 | Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cellâ€‘, and not B cellâ€‘, dependent antilymphoma immunity. <i>Blood</i> , 2009, 114, 4142-4149. | 0.6 | 32 |
| 118 | Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. <i>Cancer</i> , 2008, 113, 791-798. | 2.0 | 219 |
| 119 | Phase 2 trial of rituximab plus hyperâ€‘CVAD alternating with rituximab plus methotrexateâ€‘cytarabine for relapsed or refractory aggressive mantle cell lymphoma. <i>Cancer</i> , 2008, 113, 2734-2741. | 2.0 | 31 |
| 120 | Immunotherapy in mantle cell lymphoma: Anti-CD20-based therapy and beyond. <i>American Journal of Hematology</i> , 2008, 83, 144-149. | 2.0 | 19 |
| 121 | Phase II multicenter study of oblimersen sodium, a Bclâ€‘2 antisense oligonucleotide, in combination with rituximab in patients with recurrent Bâ€‘cell nonâ€‘Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2008, 143, 355-360. | 1.2 | 93 |
| 122 | A novel strategy for rapid and efficient isolation of human tumor-specific CD4+ and CD8+ T-cell clones. <i>Journal of Immunological Methods</i> , 2008, 331, 13-26. | 0.6 | 15 |
| 123 | Roles of Idiotype-Specific T Cells in Myeloma Cell Growth and Survival: Th1 and CTL Cells Are Tumoricidal while Th2 Cells Promote Tumor Growth. <i>Cancer Research</i> , 2008, 68, 8456-8464. | 0.4 | 61 |
| 124 | A Severe Combined Immunodeficientâ€‘hu <i>in vivo</i> Mouse Model of Human Primary Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 2154-2160. | 3.2 | 26 |
| 125 | Efficient Modulation of T-cell Response by Dual-mode, Single-carrier Delivery of Cytokine-targeted siRNA and DNA Vaccine to Antigen-presenting Cells. <i>Molecular Therapy</i> , 2008, 16, 2011-2021. | 3.7 | 61 |
| 126 | Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i> , 2008, 111, 5530-5536. | 0.6 | 294 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2008, 112, 3051-3051. | 0.6 | 5 |
| 128 | Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 243-249. | 0.9 | 9 |
| 129 | Prognostic significance of serum B-lymphocyte stimulator level in Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 269-270. | 1.7 | 16 |
| 130 | A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. <i>Blood</i> , 2007, 109, 5407-5410. | 0.6 | 18 |
| 131 | An NKT-mediated autologous vaccine generates CD4 T-cell-dependent potent antilymphoma immunity. <i>Blood</i> , 2007, 110, 2013-2019. | 0.6 | 66 |
| 132 | A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. <i>Blood</i> , 2007, 109, 5160-5163. | 0.6 | 33 |
| 133 | Anti- κ 2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. <i>Blood</i> , 2007, 110, 3028-3035. | 0.6 | 52 |
| 134 | Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. <i>Vaccine</i> , 2007, 25, 7955-7961. | 1.7 | 42 |
| 135 | Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. <i>Blood</i> , 2007, 110, 1587-1594. | 0.6 | 115 |
| 136 | Elevated serum BLyS levels in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 1869-1871. | 0.6 | 11 |
| 137 | Therapeutic Vaccine for Lymphoma. <i>Yonsei Medical Journal</i> , 2007, 48, 1. | 0.9 | 7 |
| 138 | Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. <i>Cancer</i> , 2007, 109, 77-83. | 2.0 | 48 |
| 139 | Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. <i>Cancer</i> , 2007, 109, 2481-2489. | 2.0 | 138 |
| 140 | Human C-Reactive Protein Binds Activating Fc γ 3 Receptors and Protects Myeloma Tumor Cells from Apoptosis. <i>Cancer Cell</i> , 2007, 12, 252-265. | 7.7 | 112 |
| 141 | Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: Implications for lymphomagenesis. <i>Leukemia and Lymphoma</i> , 2006, 47, 1523-1534. | 0.6 | 32 |
| 142 | Therapeutic lymphoma vaccines: importance of T-cell immunity. <i>Expert Review of Vaccines</i> , 2006, 5, 381-394. | 2.0 | 18 |
| 143 | Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. <i>Blood</i> , 2006, 107, 2432-2439. | 0.6 | 97 |
| 144 | Myeloma wrecks Treg?. <i>Blood</i> , 2006, 107, 8-9. | 0.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. <i>Blood</i> , 2006, 108, 4071-4077. | 0.6 | 87 |
| 146 | Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. <i>Blood</i> , 2006, 108, 2407-2415. | 0.6 | 71 |
| 147 | Targeting β 2-microglobulin for induction of tumor apoptosis in human hematological malignancies. <i>Cancer Cell</i> , 2006, 10, 295-307. | 7.7 | 92 |
| 148 | Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. <i>Journal of Controlled Release</i> , 2006, 113, 261-270. | 4.8 | 81 |
| 149 | Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera. <i>Journal of Immunological Methods</i> , 2006, 312, 79-93. | 0.6 | 4 |
| 150 | Dose-Related Safety and Immunogenicity of Baculovirus-Expressed Trivalent Influenza Vaccine: A Double-Blind, Controlled Trial in Adult Patients with Non-Hodgkin B Cell Lymphoma. <i>Journal of Infectious Diseases</i> , 2006, 194, 1394-1397. | 1.9 | 42 |
| 151 | 623. Polymer Microparticles Delivering a Idiotype/Chemokine Fusion DNA Vaccine Generate Protective Immunity in a Mice Model of B Cell Lymphoma. <i>Molecular Therapy</i> , 2006, 13, S240. | 3.7 | 0 |
| 152 | Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.. <i>Blood</i> , 2006, 108, 2742-2742. | 0.6 | 9 |
| 153 | Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. <i>Nature Medicine</i> , 2005, 11, 986-991. | 15.2 | 106 |
| 154 | Phase III Randomized Trial of Patient-Specific Vaccination for Previously Untreated Patients with Follicular Lymphoma in First Complete Remission: Protocol Summary and Interim Report. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 61-64. | 2.1 | 26 |
| 155 | B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. <i>Blood</i> , 2005, 106, 795-802. | 0.6 | 114 |
| 156 | Therapeutic idiotype vaccines in B lymphoproliferative diseases. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 959-963. | 1.4 | 11 |
| 157 | Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen. <i>Clinical Cancer Research</i> , 2004, 10, 8309-8317. | 3.2 | 75 |
| 158 | Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies. <i>Clinical Cancer Research</i> , 2004, 10, 1047-1056. | 3.2 | 19 |
| 159 | Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. <i>Journal of Leukocyte Biology</i> , 2004, 76, 77-85. | 1.5 | 28 |
| 160 | Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. <i>Laboratory Investigation</i> , 2004, 84, 235-244. | 1.7 | 84 |
| 161 | Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion. <i>Seminars in Oncology</i> , 2004, 31, 37-46. | 0.8 | 18 |
| 162 | Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry. <i>Proteomics</i> , 2004, 4, 1195-1203. | 1.3 | 137 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. <i>Journal of Translational Medicine</i> , 2004, 2, 9. | 1.8 | 36 |
| 164 | Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. <i>Blood</i> , 2004, 104, 1961-1969. | 0.6 | 55 |
| 165 | Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes. <i>Journal of Clinical Investigation</i> , 2004, 113, 1498-1510. | 3.9 | 57 |
| 166 | Human Autologous Tumor-Specific T-Cell Responses Induced by Liposome Encapsulated Lymphoma Membrane Proteins.. <i>Blood</i> , 2004, 104, 749-749. | 0.6 | 3 |
| 167 | Vaccination strategies for lymphomas. <i>Current Oncology Reports</i> , 2003, 5, 380-386. | 1.8 | 5 |
| 168 | Translational development of active immunotherapy for hematologic malignancies. <i>Seminars in Oncology</i> , 2003, 30, 17-22. | 0.8 | 16 |
| 169 | In vitro Priming of Myeloma Antigen-specific Allogeneic Donor T Cells with Idiotypic Pulsed Dendritic Cells. <i>Leukemia and Lymphoma</i> , 2003, 44, 1201-1208. | 0.6 | 14 |
| 170 | DNA vaccines encoding human immunodeficiency virus gp120 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. <i>Blood</i> , 2002, 100, 1153-1159. | 0.6 | 127 |
| 171 | Current Status of Recombinant Idiotypic Vaccines for the Treatment of Follicular Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 147-149. | 2.1 | 0 |
| 172 | Toll-Like Receptor 4-Dependent Activation of Dendritic Cells by Î²-Defensin 2. <i>Science</i> , 2002, 298, 1025-1029. | 6.0 | 870 |
| 173 | Mammalian defensins in immunity: more than just microbicidal. <i>Trends in Immunology</i> , 2002, 23, 291-296. | 2.9 | 647 |
| 174 | Translational development of active immunotherapy for hematologic malignancies. <i>International Journal of Hematology</i> , 2002, 76, 320-321. | 0.7 | 0 |
| 175 | Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. <i>Haematologica</i> , 2002, 87, 989-1001. | 1.7 | 51 |
| 176 | Models for Lymphoma. <i>Current Protocols in Immunology</i> , 2001, 46, Unit 20.6. | 3.6 | 1 |
| 177 | Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, R14-R19. | 1.2 | 12 |
| 178 | Immunotherapy of multiple myeloma. <i>Seminars in Hematology</i> , 2001, 38, 260-267. | 1.8 | 23 |
| 179 | Clinical Trial Designs for the Early Clinical Development of Therapeutic Cancer Vaccines. <i>Journal of Clinical Oncology</i> , 2001, 19, 1848-1854. | 0.8 | 113 |
| 180 | Novel Secondary Ig VH Gene Rearrangement and In-Frame Ig Heavy Chain Complementarity-Determining Region III Insertion/Deletion Variants in De Novo Follicular Lymphoma. <i>Journal of Immunology</i> , 2001, 166, 2235-2243. | 0.4 | 19 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 181 | Mediators of Innate Immunity That Target Immature, But Not Mature, Dendritic Cells Induce Antitumor Immunity When Genetically Fused with Nonimmunogenic Tumor Antigens. <i>Journal of Immunology</i> , 2001, 167, 6644-6653. | 0.4 | 284 |
| 182 | Designer cancer vaccines are still in fashion. <i>Nature Medicine</i> , 2000, 6, 966-968. | 15.2 | 23 |
| 183 | Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. <i>Blood</i> , 2000, 96, 2828-2833. | 0.6 | 106 |
| 184 | Approaches for Immunotherapy of Lymphomas. <i>Immunological Investigations</i> , 2000, 29, 93-95. | 1.0 | 1 |
| 185 | Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. <i>International Immunology</i> , 2000, 12, 691-700. | 1.8 | 182 |
| 186 | Serum BCL2/IgH DNA in Follicular Lymphoma Patients: A Minimal Residual Disease Marker. <i>Leukemia and Lymphoma</i> , 2000, 39, 165-172. | 0.6 | 8 |
| 187 | Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. <i>Blood</i> , 2000, 96, 2828-2833. | 0.6 | 7 |
| 188 | Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. <i>Nature Medicine</i> , 1999, 5, 1171-1177. | 15.2 | 573 |
| 189 | B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. <i>Immunological Reviews</i> , 1999, 170, 115-126. | 2.8 | 26 |
| 190 | Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. <i>Nature Biotechnology</i> , 1999, 17, 253-258. | 9.4 | 278 |
| 191 | Mechanisms of resistance against B-cell malignancies induced by vaccination against the immunoglobulin receptor: the case for T-cell immunity. , 1999, 99, 267-273. | | 1 |
| 192 | Development of Vaccine Strategies for the Treatment of B-Cell Malignancies. <i>Cancer Investigation</i> , 1997, 15, 577-587. | 0.6 | 20 |
| 193 | Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma " Long-Term Results of a Clinical Trial. <i>Blood</i> , 1997, 89, 3129-3135. | 0.6 | 461 |
| 194 | The current status of human cancer vaccines. <i>Expert Opinion on Investigational Drugs</i> , 1994, 3, 1241-1253. | 1.9 | 3 |
| 195 | Immunoglobulin idiotype antigen vaccines for the treatment of lymphomas. <i>Clinical Immunology Newsletter</i> , 1994, 14, 121-124. | 0.1 | 0 |
| 196 | MACOP-B ± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices. <i>Cancer</i> , 1993, 71, 4034-4042. | 2.0 | 9 |
| 197 | Cytotoxic T-Cell Response and In Vivo Protection Against Tumor Cells Harboring Activated ras Proto-oncogenes. <i>Journal of the National Cancer Institute</i> , 1993, 85, 1294-1302. | 3.0 | 64 |
| 198 | Induction of Immune Responses in Patients with B-Cell Lymphoma against the Surface-Immunoglobulin Idiotype Expressed by Their Tumors. <i>New England Journal of Medicine</i> , 1992, 327, 1209-1215. | 13.9 | 542 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Clinical significance of morphologic subdivision in diffuse large cell lymphoma. <i>Cancer</i> , 1991, 68, 1988-1993. | 2.0 | 48 |
| 200 | The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: Preliminary data. <i>Annals of Oncology</i> , 1991, 2, 47-50. | 0.6 | 52 |
| 201 | Follicular lymphoma: A model of lymphoid tumor progression in man. <i>Annals of Oncology</i> , 1991, 2, 115-122. | 0.6 | 24 |
| 202 | GENETICS AND IMMUNOLOGY OF THE P815-X2 MODEL11Supported by NIH Grants CA19791, CA27599, and CA27955. , 1985, , 363-367. | | 0 |
| 203 | Immune response to the H-X antigen on P815-X2. <i>Immunogenetics</i> , 1984, 20, 481-491. | 1.2 | 0 |
| 204 | Evidence for involvement of the H-2K b and I-A b genes in hybrid resistance to P815-X2. <i>Immunogenetics</i> , 1981, 13, 351-353. | 1.2 | 5 |